

# 2018 hepatitis C Drug Development- Pipeline Analysis Report

<https://marketpublishers.com/r/2F738EC9294EN.html>

Date: April 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 2F738EC9294EN

## Abstracts

With an estimated market value of over \$20 billion by 2020, the Hepatitis C industry is considered as the rapidly growing healthcare markets. Hepatitis C affects around 200 million people worldwide and is associated with highest treatment failure rates. Currently, no vaccine is available against HCV. Due to the mutations in Hepatitis C virus, development of a prophylactic vaccine is highly challenging.

The condition is classified into 6 genotypes, of which GT-1 genotype is the most prevalent. The condition is a contagious liver disease which can be either acute or chronic. It can rapidly progress into serious liver problems including cirrhosis or liver cancer.

Over 100 companies and universities are focusing on developing treatment options for Hepatitis C (HCV).

To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Hepatitis C (HCV) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Hepatitis C (HCV) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Hepatitis C (HCV) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

## Contents

### 1 TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

### 2 HEPATITIS C (HCV) PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Hepatitis C (HCV) Pipeline Snapshot

2.3 Hepatitis C (HCV) Pipeline by Phase

2.4 Hepatitis C (HCV) Pipeline by Company

2.5 Hepatitis C (HCV) Pipeline by Mechanism of Action

### 3 HEPATITIS C (HCV)- COMPANY WISE PIPELINE ANALYSIS

Achillion Pharmaceuticals

Adaptimmune

Akshaya Bio

Alios BioPharma

Alios BioPharma

Alla Chem

Amarillo Biosciences

Amarna Therapeutics BV

ARA Healthcare Pvt Ltd

Arbutus Biopharma

Array BioPharma

ARTES Biotechnology

Ascletis Inc

Atea Pharmaceuticals, Inc.

Beijing Kawin Technology Share-Holding

Beta Pharma

Biocad

Biotest Pharmaceuticals Corporation

Biotron Limited

Boehringer Ingelheim

Bolder Biotechnology

Bristol-Myers Squibb

Cenix BioScience  
Cocrystal Discovery  
Cocrystal Pharma Inc  
Conatus Pharmaceuticals Inc  
CytoPharm, Inc.  
DEKK-TEC Inc  
Dongguan HEC TaiGen Biopharmaceuticals  
Eisai Co Ltd  
F. Hoffmann-La Roche Ltd  
Fides Pharma  
FortuneRock(China)Co.,Ltd.  
Galactica Biotech  
GBF, Inc.  
GeneOne Life Science, Inc.  
Gilead Sciences  
GinkgoPharma  
GlaxoSmithKline  
Hayashibara  
HEC Pharm  
Hemosol BioPharma  
Idenix Pharmaceuticals  
Idun Pharmaceuticals  
ImmuneMed, Inc.  
Immunocore  
Inovio Pharmaceuticals  
Integrated BioTherapeutics  
InterMune Inc  
iQur Ltd  
Janssen Pharmaceuticals  
Jenken Biosciences  
JN-International Medical Corporation  
Karyopharm Therapeutics  
Kedrion SpA  
Life Arc  
Ligand Pharmaceuticals Inc  
Medarex  
Medivir AB  
Merck & Co  
Merck Sharp & Dohme Corp.

MetalloPharm  
Microbio Co., Ltd.  
Microbiotix  
MultiCell Technologies Inc  
Nabi Biopharmaceuticals  
Nanogen Biopharmaceutical Co  
Nitto BioPharma Inc  
Novalex Therapeutics Inc  
Novartis  
NovaTarg Therapeutics  
Nucorion Pharmaceuticals  
Nuron Biotech  
Okairos  
Ono Pharmaceutical Co Ltd  
Pharco Corporation  
PharmaEssentia Corporation  
Pomona Ricerca SR  
Presidio Pharmaceuticals  
PRISM Pharma  
Quark Pharmaceuticals Inc  
Regulus Therapeutics Inc  
ReiThera Srl  
Riboscience  
Roche  
Rodos BioTarget  
Santaris Pharma  
Savoy Pharmaceuticals  
SomaGenics  
Spring Bank Pharmaceuticals  
TaiGen Biotechnology  
TaiwanJ Pharmaceuticals  
TGV-Laboratories  
Therapure Biopharma  
THEVAX  
Tianjin SinoBiotech  
Trek Therapeutics  
Vakzine Projekt Management GmbH  
WhanIn Pharmaceutical  
XTL Biopharmaceuticals Ltd

## **4 HEPATITIS C (HCV) R&D PIPELINE SNAPSHOTS**

Drug wise Pipeline Details  
Therapeutic Candidate Name  
Originator  
Co-Developer/License Partner  
Orphan Drug Designation  
Development Phase  
Mechanism of Action  
Current Status  
Ongoing Clinical Trial Details

## **5 RECENT DEVELOPMENTS IN HEPATITIS C (HCV) PIPELINE**

## **6 APPENDIX**

6.1 About VPA Research  
6.2 Sources and Research Methodology

## List Of Figures

### LIST OF FIGURES

Figure 1: Hepatitis C (HCV) Pipeline by Phase, H1- 2018

Figure 2: Hepatitis C (HCV) Pipeline by Companies, H1- 2018

Figure 3: Company Wise Pipeline Drug Phases, H1- 2018

Figure 4: Hepatitis C (HCV) Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

## List Of Tables

### LIST OF TABLES

- Table 1: Hepatitis C (HCV) Pipeline by Phase, H1- 2018
- Table 2: Hepatitis C (HCV) Pipeline by Companies, H1- 2018
- Table 3: Hepatitis C (HCV) Pipeline by Mechanism of Action, H1- 2018
- Table 4: Achillion Pharmaceuticals HCV Pipeline, May 2018
- Table 5: Adaptimmune HCV Pipeline, May 2018
- Table 6: Akshaya Bio HCV Pipeline, May 2018
- Table 7: Alios BioPharma HCV Pipeline, May 2018
- Table 8: Alios BioPharma HCV Pipeline, May 2018
- Table 9: Alla Chem HCV Pipeline, May 2018
- Table 10: Amarillo Biosciences HCV Pipeline, May 2018
- Table 11: Amarna Therapeutics BV HCV Pipeline, May 2018
- Table 12: ARA Healthcare Pvt Ltd HCV Pipeline, May 2018
- Table 13: Arbutus Biopharma HCV Pipeline, May 2018
- Table 14: Array BioPharma HCV Pipeline, May 2018
- Table 15: ARTES Biotechnology HCV Pipeline, May 2018
- Table 16: Ascletis Inc HCV Pipeline, May 2018
- Table 17: Atea Pharmaceuticals, Inc. HCV Pipeline, May 2018
- Table 18: Beijing Kawin Technology Share-Holding HCV Pipeline, May 2018
- Table 19: Beta Pharma HCV Pipeline, May 2018
- Table 20: Biocad HCV Pipeline, May 2018
- Table 21: Biotest Pharmaceuticals Corporation HCV Pipeline, May 2018
- Table 22: Biotron Limited HCV Pipeline, May 2018
- Table 23: Boehringer Ingelheim HCV Pipeline, May 2018
- Table 24: Bolder Biotechnology HCV Pipeline, May 2018
- Table 25: Bristol-Myers Squibb HCV Pipeline, May 2018
- Table 26: Cenix BioScience HCV Pipeline, May 2018
- Table 27: Cocystal Discovery HCV Pipeline, May 2018
- Table 28: Cocystal Pharma Inc HCV Pipeline, May 2018
- Table 29: Conatus Pharmaceuticals Inc HCV Pipeline, May 2018
- Table 30: CytoPharm, Inc. HCV Pipeline, May 2018
- Table 31: DEKK-TEC Inc HCV Pipeline, May 2018
- Table 32: Dongguan HEC TaiGen Biopharmaceuticals HCV Pipeline, May 2018
- Table 33: Eisai Co Ltd HCV Pipeline, May 2018
- Table 34: F. Hoffmann-La Roche Ltd HCV Pipeline, May 2018
- Table 35: Fides Pharma HCV Pipeline, May 2018



- Table 36: FortuneRock(China)Co.,Ltd. HCV Pipeline, May 2018
- Table 37: Galactica Biotech HCV Pipeline, May 2018
- Table 38: GBF, Inc. HCV Pipeline, May 2018
- Table 39: GeneOne Life Science, Inc. HCV Pipeline, May 2018
- Table 40: Gilead Sciences HCV Pipeline, May 2018
- Table 41: GinkgoPharma HCV Pipeline, May 2018
- Table 42: GlaxoSmithKline HCV Pipeline, May 2018
- Table 43: Hayashibara HCV Pipeline, May 2018
- Table 44: HEC Pharm HCV Pipeline, May 2018
- Table 45: Hemosol BioPharma HCV Pipeline, May 2018
- Table 46: Idenix Pharmaceuticals HCV Pipeline, May 2018
- Table 47: Idun Pharmaceuticals HCV Pipeline, May 2018
- Table 48: ImmuneMed, Inc. HCV Pipeline, May 2018
- Table 49: Immunocore HCV Pipeline, May 2018
- Table 50: Inovio Pharmaceuticals HCV Pipeline, May 2018
- Table 51: Integrated BioTherapeutics HCV Pipeline, May 2018
- Table 52: InterMune Inc HCV Pipeline, May 2018
- Table 53: iQur Ltd HCV Pipeline, May 2018
- Table 54: Janssen Pharmaceuticals HCV Pipeline, May 2018
- Table 55: Jenken Biosciences HCV Pipeline, May 2018
- Table 56: JN-International Medical Corporation HCV Pipeline, May 2018
- Table 57: Karyopharm Therapeutics HCV Pipeline, May 2018
- Table 58: Kedrion SpA HCV Pipeline, May 2018
- Table 59: Life Arc HCV Pipeline, May 2018
- Table 60: Ligand Pharmaceuticals Inc HCV Pipeline, May 2018
- Table 61: Medarex HCV Pipeline, May 2018
- Table 62: Medivir AB HCV Pipeline, May 2018
- Table 63: Merck & Co HCV Pipeline, May 2018
- Table 64: Merck Sharp & Dohme Corp. HCV Pipeline, May 2018
- Table 65: MetalloPharm HCV Pipeline, May 2018
- Table 66: Microbio Co., Ltd. HCV Pipeline, May 2018
- Table 67: Microbiotix HCV Pipeline, May 2018
- Table 68: MultiCell Technologies Inc HCV Pipeline, May 2018
- Table 69: Nabi Biopharmaceuticals HCV Pipeline, May 2018
- Table 70: Nanogen Biopharmaceutical Co HCV Pipeline, May 2018
- Table 71: Nitto BioPharma Inc HCV Pipeline, May 2018
- Table 72: Novalex Therapeutics Inc HCV Pipeline, May 2018
- Table 73: Novartis HCV Pipeline, May 2018
- Table 74: NovaTarg Therapeutics HCV Pipeline, May 2018

- Table 75: Nucorion Pharmaceuticals HCV Pipeline, May 2018
- Table 76: Nuron Biotech HCV Pipeline, May 2018
- Table 77: Okairos HCV Pipeline, May 2018
- Table 78: Ono Pharmaceutical Co Ltd HCV Pipeline, May 2018
- Table 79: Pharco Corporation HCV Pipeline, May 2018
- Table 80: PharmaEssentia Corporation HCV Pipeline, May 2018
- Table 81: Pomona Ricerca SR HCV Pipeline, May 2018
- Table 82: Presidio Pharmaceuticals HCV Pipeline, May 2018
- Table 83: PRISM Pharma HCV Pipeline, May 2018
- Table 84: Quark Pharmaceuticals Inc HCV Pipeline, May 2018
- Table 85: Regulus Therapeutics Inc HCV Pipeline, May 2018
- Table 86: ReiThera Srl HCV Pipeline, May 2018
- Table 87: Riboscience HCV Pipeline, May 2018
- Table 88: Roche HCV Pipeline, May 2018
- Table 89: Rodos BioTarget HCV Pipeline, May 2018
- Table 90: Santaris Pharma HCV Pipeline, May 2018
- Table 91: Savoy Pharmaceuticals HCV Pipeline, May 2018
- Table 92: SomaGenics HCV Pipeline, May 2018
- Table 93: Spring Bank Pharmaceuticals HCV Pipeline, May 2018
- Table 94: TaiGen Biotechnology HCV Pipeline, May 2018
- Table 95: TaiwanJ Pharmaceuticals HCV Pipeline, May 2018
- Table 96: TGV-Laboratories HCV Pipeline, May 2018
- Table 97: Therapure Biopharma HCV Pipeline, May 2018
- Table 98: THEVAX HCV Pipeline, May 2018
- Table 99: Tianjin SinoBiotech HCV Pipeline, May 2018
- Table 100: Trek Therapeutics HCV Pipeline, May 2018
- Table 101: Vakzine Projekt Management GmbH HCV Pipeline, May 2018
- Table 102: WhanIn Pharmaceutical HCV Pipeline, May 2018
- Table 103: XTL Biopharmaceuticals Ltd HCV Pipeline, May 2018

## I would like to order

Product name: 2018 hepatitis C Drug Development- Pipeline Analysis Report

Product link: <https://marketpublishers.com/r/2F738EC9294EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2F738EC9294EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970